The synergistic effect of HDAC3 inhibitors and PD-L1 blockade restores the ability of tumor-infiltrating lymphocytes to kill DLBCL cells in a major histocompatibility complex class I (MHCI) and MHCII-dependent manner [56]. This evidence concerns the gene HDAC3 and neoplasm.